论文部分内容阅读
目的：研究中药复方肝癌宁对人肝癌细胞体内、外生长及其对甲胎蛋白(AFP)分泌的影响．方法：以小鼠移植人肝癌模型观察药物(每天10,5,2．5 g/kg)的体内抗肝癌作用．以MTT法测定复方肝癌宁(45 g/L)的体外抗肝癌活性,以ELISA检测AFP分泌量．结果：10 g/kg对小鼠移植人肝癌HepG_2移植瘤的生长有明显抑制作用,抑瘤率为54．5% (P＜0．01),且呈量效关系(r=10,P＜0．01)．与空白对照组相比,复方肝癌宁45 g/L作用4,5,6 d时体外培养的人肝癌HepG_2细胞株的生长明显抑制(7．0±1．3 vs 10．3±0．9,P＜0．05；12．1±0．4 vs 21．3±0．9,P＜0．01；15．2±0．3 vs 45．6±0．6,P＜0．01),AFP分泌量也明显减少(39．6±1 vs 54．5±3；20．8±2 vs 45．6±4；18．5±2 vs 40．2±3：均P＜0．01)．结论：中药复方肝癌宁能明显的抑制肝癌HepG_2细胞生长及AFP分泌水平．
Objective: To study the effect of hepatocarcinix on the growth of human hepatocarcinoma cells in vitro and in vivo and its effect on the secretion of AFP. Methods: The effect of anti-hepatoma in vivo on the transplanted human hepatocellular carcinoma model (10, 5 and 2.5 g / kg) was observed. The anti-hepatocarcinoma activity of compound HGF (45 g / L) in vitro was determined by MTT assay, and the secretion of AFP was detected by ELISA. Results: The inhibitory rate of 10 g / kg on the growth of HepG2 transplanted human hepatoma in mice was 54.5% (P <0.01), and the dose - effect relationship was significant (r = 10, P < 0.01). Compared with the blank control group, the growth of HepG_2 cells cultured in vitro was significantly inhibited at 45 g / L for 45 h and 6 d (7.0 ± 1.3 vs. 10.3 ± 0.9 , P <0.05; 12.1 ± 0.4 vs 21.3 ± 0.9, P <0.01; 15.2 ± 0.3 vs 45.6 ± 0.6, P <0.01 ), AFP secretion was also significantly reduced (39.6 ± 1 vs 54.5 ± 3; 20.8 ± 2 vs 45.6 ± 4; 18.5 ± 2 vs 40.2 ± 3: P <0. 01). Conclusion: HCC Ningpi can significantly inhibit HepG_2 cell growth and AFP secretion.